Clinical trial
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult…
NCT04551768 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT04551768 |
|---|---|
| Title | Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 |
| Official title | An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | COVID19 |
| Intervention type | Drug |
| Interventions | 50 mg/mL Virazole, 100 mg/mL Virazole |
| Enrollment | 51 |
| Start date | Feb 10, 2021 |
| Primary completion | Aug 17, 2021 |
| Completion | Aug 17, 2021 |
| First posted | Sep 16, 2020 |
| Last update posted | Aug 26, 2021 |
| Countries | Greece, Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: